PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Cited by (622)

Items 601–622 of 622

1. Efficacy and safety of time-of-day infusion of pemetrexed plus platinum for patients with advanced non-small cell lung cancer: A retrospective study
   Quan-An Xu, Ke-Xin Xian, Xian Xu, Pei Xie, Meng-Di Hao, Weilu Liu, Dai-Yan Zhou, Ziyi Wang, Xin-Xin I. Zeng, Xuhui Zhang · 2025 · Research Square
2. Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010–2023): A Meta-Analysis
   Fernanda Malucelli Favorito, Fábio Ynoe de Moraes, Consolación Moltó, Michelle B. Nadler, Alexandra Desnoyers, Eitan Amir, Brooke E. Wilson · 2025 · JTO Clinical and Research Reports
3. Comment on “The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell lung cancer”
   Michiel M. Smeenk, Vincent van der Noort, Cornedine Jannette de Gooijer, Willemijn S.M.E. Theelen · 2025 · Lung Cancer
4. Clinical characteristics of skin pigmentation caused by pemetrexed: a case report and literature review
   Leling Zhou, Li Chen, Xin Cao, Ying Wang, Ting Jiang · 2025 · Frontiers in Medicine
5. Trustworthy assessment of 2D model for lung CT scans
   Margherita Favali, V. Miskovic, Alberto Eusebio, Francesco Trovò, Leonardo Provenzano, Beshoy Guirges, Margherita Ruggirello, Marina Chiara Garassino, Claudia Proto, Giuseppe Lo Russo et al. · 2025 · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
6. Additional file 1 of Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
   Jaclyn Marie Beca, Walsh, Shaun, Kaiwan Raza, Stacey Hubay, Robinson, Andrew, Elena Mow, Keech, James, Chan, Kelvin K. W. · 2021 · Figshare
7. Additional file 1 of EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
   Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zihe Zhang, Ruifeng Shi, Liu, Minghui, Liu, Chao, Chen, Chen et al. · 2020 · Figshare
8. Additional file 1 of Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
   Wang, Kang, Zhenxue Fu, Sun, Guanxing, Yancui Ran, Lv, Nannan, Wang, Enbo, Huan Ding · 2024 · Figshare
9. Additional file 2 of Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
   Wang, Kang, Zhenxue Fu, Sun, Guanxing, Yancui Ran, Lv, Nannan, Wang, Enbo, Huan Ding · 2024 · Figshare
10. Additional file 1 of High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
    Issei Sumiyoshi, Takahiro Okabe, Shinsaku Togo, Takagi, Haruhi, Hiroaki Motomura, Ochi, Yusuke, Shimada, Naoko, Haraguchi, Mizuki, Rina Shibayama, Fujimoto, Yuichi et al. · 2021 · Figshare
11. Drug‐Induced Eyelid Edema: A Systematic Review
    Jacopo Tartaglia, Ina Tudurachi, Fortunato Cassalia, Laura Gnesotto, Deris Gianni Boemo, Stefano Piaserico · 2025 · Dermatologic Therapy
12. Additional file 2 of EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
    Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zihe Zhang, Ruifeng Shi, Liu, Minghui, Liu, Chao, Chen, Chen et al. · 2020 · Figshare
13. Additional file 3 of EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
    Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zihe Zhang, Ruifeng Shi, Liu, Minghui, Liu, Chao, Chen, Chen et al. · 2020 · Figshare
14. Additional file 1 of Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario
    Nadal, Ernest, Dolores Bautista, Cabezón-Gutiérrez, Luis, Ana Laura Ortega, Torres, Héctor, David Carcedo, Lucía Ruiz de Alda, J. F. García, Paula Vieitez, Federico Rojo · 2021 · Figshare
15. A review of the current evidence for maintenance therapy in gastric cancer
    Xinpu Han, Yu Zhang, Qiuyue Fan, Jiahui Yu, Liyuan Lv, Ya Li, Li Hou · 2026 · Frontiers in Pharmacology
16. Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs. immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study
    Zijian Huang, Shiqi Mei, J I N Liu, Qiuyi Zhang, Zhihua Li, Guanming Jiang, Fen Wang, Chanyuan Zhang, Chang Lu, Mingfeng Zhang et al. · 2026 · Chinese Medical Journal
17. Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis
    Garth William Strohbehn, Molly C. Tokaz, Daniel Sanghoon Shin, Shadia Ibrahim Jalal, Hannah F. Tavalire, Derek J. Gyori, Julie A. Moeller, Brian Gregory Bazzell, Michael J. Kelley, A. Mark Fendrick et al. · 2026 · JCO Oncology Practice
18. Association Between Cumulative Chemotherapy Exposure and Survival Outcomes in Advanced Biliary Tract Cancer
    Van Khanh Nguyen, Hisashi Kosaka, Kosuke Matsui, Hideyuki Matsushima, Hidekazu Yamamoto, Gozo Kiguchi, Takuya Ohigashi, Thanh Tung Lai, Hoang Hai Duong, Kyoko Inoue et al. · 2026 · Cancers
19. "What really works for us?" exploring therapeutic strategies for non-small cell lung cancer: an umbrella review of systematic reviews and meta-analyses.
    Xin-Yi Zhang, Yimeng Wang, Yiming Guan, Ruoyi Qu · 2026 · Clinical and Translational Oncology
20. Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment
    Mingtai Li, Zhiqing Wu, Xin Zheng, Yanhong Zhu, Yuxuan Wu, Jiaxin He, Xin Wu, Jingtong Xu, Yinyin Qin · 2026 · Current Treatment Options in Oncology
21. Long-term safety of first-line osimertinib plus platinum–pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2
    David Planchard, Pasi Antero Janne, James C. H. Yang, Kunihiko Kobayashi, Natalia Valdiviezo, Yun Fan, Tae Min Kim, M.H. Leiva Gálvez, Kazumi Nishino, Bivas Biswas et al. · 2026 · Lung Cancer
22. PemToxTrial: An Observational Study of PEMetrexed-Associated Severe HematoTOXicity in Lung Adenocarcinoma with Bone Metastases
    Christian Riedel, Christian Neumann, Arash Moghaddam, Arthur Bauer, P Büchele, Konrad Steinestel, Michael Grunert, Jan Sölter, Niklas Gebauer, Annette Arndt et al. · 2026 · Cancers